GlassScriptPhysician profile
Stacy K Robison
NPI 1346271798
$2,715.99
in general payments reported to CMS, 2019-2025
25 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $701 · 2022: $597 · 2023: $625 · 2024: $443 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.56 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $393.90 | 2021-2025 | Belbuca, Xtampza |
| Lundbeck LLC | $237.43 | 2022-2025 | Vyepti |
| Pfizer INC. | $201.92 | 2023-2025 | |
| Indivior INC. | $177.61 | 2021-2025 | Sublocade |
| Amgen INC. | $120.46 | 2021-2022 | |
| Averitas Pharma INC. | $109.59 | 2024-2025 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $108.70 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $86.12 | 2022 | |
| Virtus Pharmaceuticals LLC | $83.85 | 2021 | |
| Idorsia Pharmaceuticals US INC | $68.50 | 2022-2023 | Quviviq |
| Medtronic, INC. | $52.87 | 2023 | Intellis Adaptivestim |
| Lilly USA, LLC | $52.54 | 2021-2023 | Emgality |
| Biodelivery Sciences International, INC. | $48.14 | 2021 | |
| Arbor Pharmaceuticals, INC. | $47.16 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $36.04 | 2021 | |
| Globus Medical, INC. | $33.79 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.72 | 2022-2025 | Relistor |
| Biohaven Pharmaceuticals, INC. | $32.50 | 2021 | |
| Merck Sharp & Dohme LLC | $26.53 | 2022 | |
| Jazz Pharmaceuticals INC. | $26.46 | 2021 | |
| Axsome Therapeutics, INC. | $22.82 | 2025 | Symbravo |
| Almatica Pharma LLC | $17.34 | 2021 | |
| Nevro Corp. | $16.25 | 2021 | |
| Redhill Biopharma INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.